Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $13.75 Consensus PT from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $13.75.

TBPH has been the subject of a number of research analyst reports. StockNews.com lowered shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 10th. Leerink Partnrs lowered shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 6th. TD Cowen dropped their target price on shares of Theravance Biopharma from $10.00 to $9.00 and set a “hold” rating for the company in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research note on Monday, September 16th. Finally, Leerink Partners cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $15.00 to $10.00 in a research note on Tuesday, August 6th.

Insider Buying and Selling at Theravance Biopharma

In other news, major shareholder Eli Samaha acquired 999,800 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was bought at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the transaction, the insider now directly owns 9,511,150 shares in the company, valued at approximately $74,186,970. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the transaction, the senior vice president now directly owns 335,965 shares in the company, valued at approximately $3,023,685. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Eli Samaha acquired 999,800 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were bought at an average price of $7.80 per share, with a total value of $7,798,440.00. Following the completion of the transaction, the insider now owns 9,511,150 shares in the company, valued at $74,186,970. The disclosure for this purchase can be found here. Company insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in Theravance Biopharma during the second quarter worth $986,000. Marshall Wace LLP raised its stake in shares of Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company’s stock worth $2,523,000 after acquiring an additional 135,426 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Theravance Biopharma by 141.0% in the second quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company’s stock worth $1,414,000 after buying an additional 93,702 shares during the period. XTX Topco Ltd bought a new stake in Theravance Biopharma in the second quarter valued at $129,000. Finally, Hsbc Holdings PLC bought a new stake in Theravance Biopharma in the second quarter valued at $108,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Stock Up 0.5 %

Shares of NASDAQ TBPH opened at $8.10 on Wednesday. The stock has a market capitalization of $396.25 million, a price-to-earnings ratio of -9.42 and a beta of 0.24. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71. The stock’s fifty day simple moving average is $8.52 and its 200 day simple moving average is $8.84.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The firm had revenue of $14.26 million for the quarter, compared to analysts’ expectations of $15.81 million. During the same period last year, the business earned ($0.28) earnings per share. As a group, analysts anticipate that Theravance Biopharma will post -1.04 earnings per share for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.